New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data
•Inherent features of PID contribute to manifestations and outcome of polio infection.•Cytotoxic cellular mechanisms may contribute to the development of vaccine paralysis.•T-cell interactions with poliovirus infected cells play a role in infection clearance.•Paralysis, PID type, and income level in...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2018-03, Vol.36 (13), p.1711-1719 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1719 |
|---|---|
| container_issue | 13 |
| container_start_page | 1711 |
| container_title | Vaccine |
| container_volume | 36 |
| creator | Shaghaghi, Mohammadreza Soleyman-jahi, Saeed Abolhassani, Hassan Yazdani, Reza Azizi, Gholamreza Rezaei, Nima Barbouche, Mohamed-Ridha McKinlay, Mark A. Aghamohammadi, Asghar |
| description | •Inherent features of PID contribute to manifestations and outcome of polio infection.•Cytotoxic cellular mechanisms may contribute to the development of vaccine paralysis.•T-cell interactions with poliovirus infected cells play a role in infection clearance.•Paralysis, PID type, and income level independently influence patients’ survival.•We explained the trend of vaccine-derived poliovirus genomic evolution.
Widespread administration of oral poliovirus vaccine (OPV) has decreased global incidence of poliomyelitis by ≈99.9%. However, the emergence of vaccine-derived polioviruses (VDPVs) is threatening polio-eradication program. Primary immunodeficiency (PID) patients are at higher risks of vaccine-associated paralytic poliomyelitis (VAPP) and prolonged excretion of immunodeficiency-associated VDPV (iVDPV).
We searched Embase, Medline, Science direct, Scopus, Web of Science, and CDC and WHO databases by 30 September 2016, for all reports of iVDPV cases. Patient-level data were extracted form eligible studies. Data on immunization coverage and income-level of countries were extracted from WHO/UNICEF and the WORLD BANK databases, respectively. We assessed bivariate associations between immunological, clinical, and virological parameters, and exploited multivariable modeling to identify independent determinants of poliovirus evolution and patients’ outcomes. Study protocol was registered with PROSPERO (CRD42016052931).
4329 duplicate-removed titles were screened. A total of 107 iVDPV cases were identified from 68 eligible articles. The majority of cases were from higher income countries with high polio-immunization coverage. 74 (69.81%) patients developed VAPP. Combined immunodeficiency patients showed lower rates of VAPP (p |
| doi_str_mv | 10.1016/j.vaccine.2018.02.059 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_490227</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X18302469</els_id><sourcerecordid>2012441126</sourcerecordid><originalsourceid>FETCH-LOGICAL-c517t-3732e0a20d801cd93a0b77a9dd8d1f594bbf3348679a98879b049517fd3e22f23</originalsourceid><addsrcrecordid>eNqFksFu1DAQhiMEokvhEUCRuMAhYewka1scqqqiFGkFF5C4WY496XpJ4mAnqfY1eGKcbqgEF062R98_M55_kuQlgZwA2b475LPS2vaYUyA8B5pDJR4lG8JZkdGK8MfJBui2zEoC38-SZyEcAKAqiHianFFRMs6qapP8-ox3qe2Dvd2PIV5Glw77Y7BuUOPete72mLomtV039c5gY7XFXh8zFYLTVo1o0rWNzKC3c3wPrrVutn5a0jWoR-v692k4hhE7NVqdepxtLBrTuhl9WqUGtTIYlohRo3qePGlUG_DFep4n364_fL26yXZfPn66utxluiJszApWUARFwXAg2ohCQc2YEsZwQ5pKlHXdFEXJt0wowTkTNZQiKhtTIKUNLc6T7JQ33OEw1XLwtlP-KJ2ycg39iDeUpQBKWeTfnvi9av-Cby53conBMnte0plE9s2JHbz7OWEYZWeDxrZVPbopSArAC0aggoi-_gc9uMn38eeRIrQsCaHbSFUnSnsXgsfmoQMCclkIeZCrE4uMS6AyLkTUvVqzT3WH5kH1ZwMicHECMI46GuNluPcYjfXRPGmc_U-J3-Zxy6w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2012441126</pqid></control><display><type>article</type><title>New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data</title><source>Elsevier ScienceDirect Journals</source><creator>Shaghaghi, Mohammadreza ; Soleyman-jahi, Saeed ; Abolhassani, Hassan ; Yazdani, Reza ; Azizi, Gholamreza ; Rezaei, Nima ; Barbouche, Mohamed-Ridha ; McKinlay, Mark A. ; Aghamohammadi, Asghar</creator><creatorcontrib>Shaghaghi, Mohammadreza ; Soleyman-jahi, Saeed ; Abolhassani, Hassan ; Yazdani, Reza ; Azizi, Gholamreza ; Rezaei, Nima ; Barbouche, Mohamed-Ridha ; McKinlay, Mark A. ; Aghamohammadi, Asghar</creatorcontrib><description>•Inherent features of PID contribute to manifestations and outcome of polio infection.•Cytotoxic cellular mechanisms may contribute to the development of vaccine paralysis.•T-cell interactions with poliovirus infected cells play a role in infection clearance.•Paralysis, PID type, and income level independently influence patients’ survival.•We explained the trend of vaccine-derived poliovirus genomic evolution.
Widespread administration of oral poliovirus vaccine (OPV) has decreased global incidence of poliomyelitis by ≈99.9%. However, the emergence of vaccine-derived polioviruses (VDPVs) is threatening polio-eradication program. Primary immunodeficiency (PID) patients are at higher risks of vaccine-associated paralytic poliomyelitis (VAPP) and prolonged excretion of immunodeficiency-associated VDPV (iVDPV).
We searched Embase, Medline, Science direct, Scopus, Web of Science, and CDC and WHO databases by 30 September 2016, for all reports of iVDPV cases. Patient-level data were extracted form eligible studies. Data on immunization coverage and income-level of countries were extracted from WHO/UNICEF and the WORLD BANK databases, respectively. We assessed bivariate associations between immunological, clinical, and virological parameters, and exploited multivariable modeling to identify independent determinants of poliovirus evolution and patients’ outcomes. Study protocol was registered with PROSPERO (CRD42016052931).
4329 duplicate-removed titles were screened. A total of 107 iVDPV cases were identified from 68 eligible articles. The majority of cases were from higher income countries with high polio-immunization coverage. 74 (69.81%) patients developed VAPP. Combined immunodeficiency patients showed lower rates of VAPP (p < .001) and infection clearance (p = .02), compared to humoral immunodeficiency patients. The rate of poliovirus genomic evolution was higher at early stages of replication, decreasing over time until reaching a steady state. Independent of replication duration, higher extent (p = .04) and rates (p = .03) of genome divergence contributed to a less likelihood of virus clearance. PID type (p < .001), VAPP occurrence (p = .008), and income-level of country (p = .04) independently influenced patients’ survival.
With the use of OPV, new iVDPVs will emerge independent of the rate of immunization coverage. Inherent features of PIDs contribute to the clinical course of iVDPV infection and virus evolution. This finding could shed further light on poliomyelitis pathogenesis and iVDPV evolution pattern. It also has implications for public health, the polio eradication effort and the development of effective antiviral interventions.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>EISSN: 0264-410X</identifier><identifier>DOI: 10.1016/j.vaccine.2018.02.059</identifier><identifier>PMID: 29478755</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Animals ; Bivariate analysis ; Child, Preschool ; Divergence ; Eradication ; Evolution ; Excretion ; Female ; Genomes ; History, 20th Century ; History, 21st Century ; Humans ; Immunization ; Immunocompromised Host ; Immunodeficiency ; Immunologic Deficiency Syndromes/complications ; Immunologic Deficiency Syndromes/diagnosis ; Immunology ; Income ; Infant ; Infections ; Life Sciences ; Male ; Microbiology and Parasitology ; Mutation ; Odds Ratio ; Oral poliovirus vaccine ; Paralysis ; Parameter identification ; Pathogenesis ; Patients ; Poliomyelitis ; Poliomyelitis/epidemiology ; Poliomyelitis/etiology ; Poliomyelitis/history ; Poliomyelitis/prevention & control ; Poliovirus Vaccine, Oral/adverse effects ; Poliovirus Vaccines/adverse effects ; Poliovirus/classification ; Poliovirus/genetics ; Poliovirus/immunology ; Primary immunodeficiencies ; Primary immunodeficiency ; Proportional Hazards Models ; Public health ; Replication ; Risk factors ; Serogroup ; Systematic review ; Vaccination/adverse effects ; Vaccine-associated paralytic poliomyelitis ; Vaccine-derived poliovirus ; Vaccines ; Vaccinology ; Viral infections ; Virology ; Viruses</subject><ispartof>Vaccine, 2018-03, Vol.36 (13), p.1711-1719</ispartof><rights>2018</rights><rights>Copyright © 2018. Published by Elsevier Ltd.</rights><rights>Copyright Elsevier Limited Mar 20, 2018</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c517t-3732e0a20d801cd93a0b77a9dd8d1f594bbf3348679a98879b049517fd3e22f23</citedby><cites>FETCH-LOGICAL-c517t-3732e0a20d801cd93a0b77a9dd8d1f594bbf3348679a98879b049517fd3e22f23</cites><orcidid>0000-0002-4838-0407</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X18302469$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29478755$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01873842$$DView record in HAL$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:137957295$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Shaghaghi, Mohammadreza</creatorcontrib><creatorcontrib>Soleyman-jahi, Saeed</creatorcontrib><creatorcontrib>Abolhassani, Hassan</creatorcontrib><creatorcontrib>Yazdani, Reza</creatorcontrib><creatorcontrib>Azizi, Gholamreza</creatorcontrib><creatorcontrib>Rezaei, Nima</creatorcontrib><creatorcontrib>Barbouche, Mohamed-Ridha</creatorcontrib><creatorcontrib>McKinlay, Mark A.</creatorcontrib><creatorcontrib>Aghamohammadi, Asghar</creatorcontrib><title>New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•Inherent features of PID contribute to manifestations and outcome of polio infection.•Cytotoxic cellular mechanisms may contribute to the development of vaccine paralysis.•T-cell interactions with poliovirus infected cells play a role in infection clearance.•Paralysis, PID type, and income level independently influence patients’ survival.•We explained the trend of vaccine-derived poliovirus genomic evolution.
Widespread administration of oral poliovirus vaccine (OPV) has decreased global incidence of poliomyelitis by ≈99.9%. However, the emergence of vaccine-derived polioviruses (VDPVs) is threatening polio-eradication program. Primary immunodeficiency (PID) patients are at higher risks of vaccine-associated paralytic poliomyelitis (VAPP) and prolonged excretion of immunodeficiency-associated VDPV (iVDPV).
We searched Embase, Medline, Science direct, Scopus, Web of Science, and CDC and WHO databases by 30 September 2016, for all reports of iVDPV cases. Patient-level data were extracted form eligible studies. Data on immunization coverage and income-level of countries were extracted from WHO/UNICEF and the WORLD BANK databases, respectively. We assessed bivariate associations between immunological, clinical, and virological parameters, and exploited multivariable modeling to identify independent determinants of poliovirus evolution and patients’ outcomes. Study protocol was registered with PROSPERO (CRD42016052931).
4329 duplicate-removed titles were screened. A total of 107 iVDPV cases were identified from 68 eligible articles. The majority of cases were from higher income countries with high polio-immunization coverage. 74 (69.81%) patients developed VAPP. Combined immunodeficiency patients showed lower rates of VAPP (p < .001) and infection clearance (p = .02), compared to humoral immunodeficiency patients. The rate of poliovirus genomic evolution was higher at early stages of replication, decreasing over time until reaching a steady state. Independent of replication duration, higher extent (p = .04) and rates (p = .03) of genome divergence contributed to a less likelihood of virus clearance. PID type (p < .001), VAPP occurrence (p = .008), and income-level of country (p = .04) independently influenced patients’ survival.
With the use of OPV, new iVDPVs will emerge independent of the rate of immunization coverage. Inherent features of PIDs contribute to the clinical course of iVDPV infection and virus evolution. This finding could shed further light on poliomyelitis pathogenesis and iVDPV evolution pattern. It also has implications for public health, the polio eradication effort and the development of effective antiviral interventions.</description><subject>Animals</subject><subject>Bivariate analysis</subject><subject>Child, Preschool</subject><subject>Divergence</subject><subject>Eradication</subject><subject>Evolution</subject><subject>Excretion</subject><subject>Female</subject><subject>Genomes</subject><subject>History, 20th Century</subject><subject>History, 21st Century</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunocompromised Host</subject><subject>Immunodeficiency</subject><subject>Immunologic Deficiency Syndromes/complications</subject><subject>Immunologic Deficiency Syndromes/diagnosis</subject><subject>Immunology</subject><subject>Income</subject><subject>Infant</subject><subject>Infections</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Microbiology and Parasitology</subject><subject>Mutation</subject><subject>Odds Ratio</subject><subject>Oral poliovirus vaccine</subject><subject>Paralysis</subject><subject>Parameter identification</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Poliomyelitis</subject><subject>Poliomyelitis/epidemiology</subject><subject>Poliomyelitis/etiology</subject><subject>Poliomyelitis/history</subject><subject>Poliomyelitis/prevention & control</subject><subject>Poliovirus Vaccine, Oral/adverse effects</subject><subject>Poliovirus Vaccines/adverse effects</subject><subject>Poliovirus/classification</subject><subject>Poliovirus/genetics</subject><subject>Poliovirus/immunology</subject><subject>Primary immunodeficiencies</subject><subject>Primary immunodeficiency</subject><subject>Proportional Hazards Models</subject><subject>Public health</subject><subject>Replication</subject><subject>Risk factors</subject><subject>Serogroup</subject><subject>Systematic review</subject><subject>Vaccination/adverse effects</subject><subject>Vaccine-associated paralytic poliomyelitis</subject><subject>Vaccine-derived poliovirus</subject><subject>Vaccines</subject><subject>Vaccinology</subject><subject>Viral infections</subject><subject>Virology</subject><subject>Viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><issn>0264-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFksFu1DAQhiMEokvhEUCRuMAhYewka1scqqqiFGkFF5C4WY496XpJ4mAnqfY1eGKcbqgEF062R98_M55_kuQlgZwA2b475LPS2vaYUyA8B5pDJR4lG8JZkdGK8MfJBui2zEoC38-SZyEcAKAqiHianFFRMs6qapP8-ox3qe2Dvd2PIV5Glw77Y7BuUOPete72mLomtV039c5gY7XFXh8zFYLTVo1o0rWNzKC3c3wPrrVutn5a0jWoR-v692k4hhE7NVqdepxtLBrTuhl9WqUGtTIYlohRo3qePGlUG_DFep4n364_fL26yXZfPn66utxluiJszApWUARFwXAg2ohCQc2YEsZwQ5pKlHXdFEXJt0wowTkTNZQiKhtTIKUNLc6T7JQ33OEw1XLwtlP-KJ2ycg39iDeUpQBKWeTfnvi9av-Cby53conBMnte0plE9s2JHbz7OWEYZWeDxrZVPbopSArAC0aggoi-_gc9uMn38eeRIrQsCaHbSFUnSnsXgsfmoQMCclkIeZCrE4uMS6AyLkTUvVqzT3WH5kH1ZwMicHECMI46GuNluPcYjfXRPGmc_U-J3-Zxy6w</recordid><startdate>20180320</startdate><enddate>20180320</enddate><creator>Shaghaghi, Mohammadreza</creator><creator>Soleyman-jahi, Saeed</creator><creator>Abolhassani, Hassan</creator><creator>Yazdani, Reza</creator><creator>Azizi, Gholamreza</creator><creator>Rezaei, Nima</creator><creator>Barbouche, Mohamed-Ridha</creator><creator>McKinlay, Mark A.</creator><creator>Aghamohammadi, Asghar</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><general>Elsevier</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><scope>ADTPV</scope><scope>AOWAS</scope><orcidid>https://orcid.org/0000-0002-4838-0407</orcidid></search><sort><creationdate>20180320</creationdate><title>New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data</title><author>Shaghaghi, Mohammadreza ; Soleyman-jahi, Saeed ; Abolhassani, Hassan ; Yazdani, Reza ; Azizi, Gholamreza ; Rezaei, Nima ; Barbouche, Mohamed-Ridha ; McKinlay, Mark A. ; Aghamohammadi, Asghar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c517t-3732e0a20d801cd93a0b77a9dd8d1f594bbf3348679a98879b049517fd3e22f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Bivariate analysis</topic><topic>Child, Preschool</topic><topic>Divergence</topic><topic>Eradication</topic><topic>Evolution</topic><topic>Excretion</topic><topic>Female</topic><topic>Genomes</topic><topic>History, 20th Century</topic><topic>History, 21st Century</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunocompromised Host</topic><topic>Immunodeficiency</topic><topic>Immunologic Deficiency Syndromes/complications</topic><topic>Immunologic Deficiency Syndromes/diagnosis</topic><topic>Immunology</topic><topic>Income</topic><topic>Infant</topic><topic>Infections</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Microbiology and Parasitology</topic><topic>Mutation</topic><topic>Odds Ratio</topic><topic>Oral poliovirus vaccine</topic><topic>Paralysis</topic><topic>Parameter identification</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Poliomyelitis</topic><topic>Poliomyelitis/epidemiology</topic><topic>Poliomyelitis/etiology</topic><topic>Poliomyelitis/history</topic><topic>Poliomyelitis/prevention & control</topic><topic>Poliovirus Vaccine, Oral/adverse effects</topic><topic>Poliovirus Vaccines/adverse effects</topic><topic>Poliovirus/classification</topic><topic>Poliovirus/genetics</topic><topic>Poliovirus/immunology</topic><topic>Primary immunodeficiencies</topic><topic>Primary immunodeficiency</topic><topic>Proportional Hazards Models</topic><topic>Public health</topic><topic>Replication</topic><topic>Risk factors</topic><topic>Serogroup</topic><topic>Systematic review</topic><topic>Vaccination/adverse effects</topic><topic>Vaccine-associated paralytic poliomyelitis</topic><topic>Vaccine-derived poliovirus</topic><topic>Vaccines</topic><topic>Vaccinology</topic><topic>Viral infections</topic><topic>Virology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shaghaghi, Mohammadreza</creatorcontrib><creatorcontrib>Soleyman-jahi, Saeed</creatorcontrib><creatorcontrib>Abolhassani, Hassan</creatorcontrib><creatorcontrib>Yazdani, Reza</creatorcontrib><creatorcontrib>Azizi, Gholamreza</creatorcontrib><creatorcontrib>Rezaei, Nima</creatorcontrib><creatorcontrib>Barbouche, Mohamed-Ridha</creatorcontrib><creatorcontrib>McKinlay, Mark A.</creatorcontrib><creatorcontrib>Aghamohammadi, Asghar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shaghaghi, Mohammadreza</au><au>Soleyman-jahi, Saeed</au><au>Abolhassani, Hassan</au><au>Yazdani, Reza</au><au>Azizi, Gholamreza</au><au>Rezaei, Nima</au><au>Barbouche, Mohamed-Ridha</au><au>McKinlay, Mark A.</au><au>Aghamohammadi, Asghar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2018-03-20</date><risdate>2018</risdate><volume>36</volume><issue>13</issue><spage>1711</spage><epage>1719</epage><pages>1711-1719</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><eissn>0264-410X</eissn><abstract>•Inherent features of PID contribute to manifestations and outcome of polio infection.•Cytotoxic cellular mechanisms may contribute to the development of vaccine paralysis.•T-cell interactions with poliovirus infected cells play a role in infection clearance.•Paralysis, PID type, and income level independently influence patients’ survival.•We explained the trend of vaccine-derived poliovirus genomic evolution.
Widespread administration of oral poliovirus vaccine (OPV) has decreased global incidence of poliomyelitis by ≈99.9%. However, the emergence of vaccine-derived polioviruses (VDPVs) is threatening polio-eradication program. Primary immunodeficiency (PID) patients are at higher risks of vaccine-associated paralytic poliomyelitis (VAPP) and prolonged excretion of immunodeficiency-associated VDPV (iVDPV).
We searched Embase, Medline, Science direct, Scopus, Web of Science, and CDC and WHO databases by 30 September 2016, for all reports of iVDPV cases. Patient-level data were extracted form eligible studies. Data on immunization coverage and income-level of countries were extracted from WHO/UNICEF and the WORLD BANK databases, respectively. We assessed bivariate associations between immunological, clinical, and virological parameters, and exploited multivariable modeling to identify independent determinants of poliovirus evolution and patients’ outcomes. Study protocol was registered with PROSPERO (CRD42016052931).
4329 duplicate-removed titles were screened. A total of 107 iVDPV cases were identified from 68 eligible articles. The majority of cases were from higher income countries with high polio-immunization coverage. 74 (69.81%) patients developed VAPP. Combined immunodeficiency patients showed lower rates of VAPP (p < .001) and infection clearance (p = .02), compared to humoral immunodeficiency patients. The rate of poliovirus genomic evolution was higher at early stages of replication, decreasing over time until reaching a steady state. Independent of replication duration, higher extent (p = .04) and rates (p = .03) of genome divergence contributed to a less likelihood of virus clearance. PID type (p < .001), VAPP occurrence (p = .008), and income-level of country (p = .04) independently influenced patients’ survival.
With the use of OPV, new iVDPVs will emerge independent of the rate of immunization coverage. Inherent features of PIDs contribute to the clinical course of iVDPV infection and virus evolution. This finding could shed further light on poliomyelitis pathogenesis and iVDPV evolution pattern. It also has implications for public health, the polio eradication effort and the development of effective antiviral interventions.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>29478755</pmid><doi>10.1016/j.vaccine.2018.02.059</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-4838-0407</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2018-03, Vol.36 (13), p.1711-1719 |
| issn | 0264-410X 1873-2518 0264-410X |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_490227 |
| source | Elsevier ScienceDirect Journals |
| subjects | Animals Bivariate analysis Child, Preschool Divergence Eradication Evolution Excretion Female Genomes History, 20th Century History, 21st Century Humans Immunization Immunocompromised Host Immunodeficiency Immunologic Deficiency Syndromes/complications Immunologic Deficiency Syndromes/diagnosis Immunology Income Infant Infections Life Sciences Male Microbiology and Parasitology Mutation Odds Ratio Oral poliovirus vaccine Paralysis Parameter identification Pathogenesis Patients Poliomyelitis Poliomyelitis/epidemiology Poliomyelitis/etiology Poliomyelitis/history Poliomyelitis/prevention & control Poliovirus Vaccine, Oral/adverse effects Poliovirus Vaccines/adverse effects Poliovirus/classification Poliovirus/genetics Poliovirus/immunology Primary immunodeficiencies Primary immunodeficiency Proportional Hazards Models Public health Replication Risk factors Serogroup Systematic review Vaccination/adverse effects Vaccine-associated paralytic poliomyelitis Vaccine-derived poliovirus Vaccines Vaccinology Viral infections Virology Viruses |
| title | New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T07%3A01%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20insights%20into%20physiopathology%20of%20immunodeficiency-associated%20vaccine-derived%20poliovirus%20infection;%20systematic%20review%20of%20over%205%20decades%20of%20data&rft.jtitle=Vaccine&rft.au=Shaghaghi,%20Mohammadreza&rft.date=2018-03-20&rft.volume=36&rft.issue=13&rft.spage=1711&rft.epage=1719&rft.pages=1711-1719&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2018.02.059&rft_dat=%3Cproquest_swepu%3E2012441126%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2012441126&rft_id=info:pmid/29478755&rft_els_id=S0264410X18302469&rfr_iscdi=true |